



NDA 008762/S-050
NDA 010151/S-038

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Denise S. Tindle, M.S.
Director, Worldwide Regulatory Strategy
445 Eastern Point Road
Groton, CT 06340

Dear Ms. Tindle:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received May 29, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dilantin - 125 (phenytoin) Oral Suspension and Dilantin (phenytoin) Injection.

We also acknowledge receipt of your amendments dated January 17, 2014.

These "Changes Being Effected" supplemental new drug applications provide for the addition of:

- Albendazole to the Drug Interactions section
- Vertigo and acute hepatic failure to the Adverse Reactions section

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your January 17, 2014, submission includes final printed labeling (FPL) for your package insert. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Laurie Kelley, PA-C, Regulatory Project Manager, via telephone at (301) 796-5068 or via email at Laurie.Kelley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):

Package Insert
Medication Guide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
01/24/2014